Actavis UK’s ‘Excessive’ Price Hikes Targeted In Latest Competition Inquiry
Executive Summary
The UK competition authority has provisionally found that Actavis UK imposed “excessive” price rises on its generic version of hydrocortisone for the life-threatening condition, adrenal insufficiency. The case has similarities to the price increases on phenytoin capsules, for which Pfizer and Flynn Pharma were recently fined.
You may also be interested in...
UK Competition Regulator Steps Up Hydrocortisone Probe
Two generics firms have been provisionally found to have breached competition law by reaching agreements intended to delay the entry of competing products.
UK Competition Body Steps Up Generic Hydrocortisone Probe
Two generics firms have been provisionally found to have breached competition law by reaching agreements intended to delay the entry of competing products.
‘Excessive Pricing’ Inquiry Widens As EC’s First Antitrust Price Probe Targets Aspen Pharma
The litany of complaints against pharmaceutical companies for imposing “excessive” prices on generic drugs is growing after the European Commission decided to pursue Aspen Pharma over price rises imposed on a range of anticancer products it acquired from GSK.